Clinical Trial Update: GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L) [Phase 2]

View source ↗

Summary

GRN1005 was studied in a Phase 2 trial (GRABM-L) for non-small cell lung cancer with brain metastases. The study is terminated and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• GRN1005

Snippet

Sponsor: Angiochem Inc | Conditions: Non-small Cell Lung Cancer (NSCLC) With Brain Metastases | Phase 2 | Status: TERMINATED | Results posted: 2015-12-14